Kapural Leonardo, Syed Shah Nemath, Fang Zi-Ping, Mekhail Nagy
Carolinas Pain Institute, Winston-Salem, NC, USA.
Neuros Medical, Inc., Willoughby Hills, OH, USA.
J Pain Res. 2022 Jun 3;15:1623-1631. doi: 10.2147/JPR.S353674. eCollection 2022.
Chronic pain that follows amputation of a limb is reported as "one of the most severe pains in the human experience," due to the magnitude of tissue injury and the multiple potential of pain generators at the local peripheral, spinal, and cortical levels. The Altius® System was developed to deliver high-frequency nerve block (HFNB) therapy via a cuff electrode applied to the peripheral nerve(s) and an implantable pulse generator. We report a novel clinical trial design for the first study of an active-implantable medical device in subjects with lower-limb post-amputation pain utilizing a multicenter, double-blinded, randomized, active-sham controlled clinical study protocol called QUEST, which is an ongoing investigational device exemption study to support United States Food and Drug Administration approval.
The study enrollment of 180 subjects was completed in September 2021. Subjects were randomized 1:1 to the treatment group or the active-sham control group for the 3-month primary effectiveness and safety endpoints. After month 3, the active-sham control program group crossed over to the treatment program group and all subjects continued to the 12-month study endpoint. Study effectiveness success is determined by a superiority test between responder rates in the treatment and control groups at 3 months. A responder is defined as someone who experiences a 50% or greater reduction in pain scores - after a 30-minute treatment session - for more than 50% of all pain episodes in which the treatment was used.
The QUEST study design employs an active-sham control group to objectively assess the effectiveness of HFNB therapy. Additionally, the electronic diary repeated measures data collection in QUEST is expected to reduce the intra-subject variation typically observed in pain treatment studies. Finally, the longitudinal measurement of health-related quality of life and use of pain medication may, for example, show effectiveness in reducing opioid use over time.
肢体截肢后的慢性疼痛被报道为“人类经历中最剧烈的疼痛之一”,这是由于组织损伤的程度以及局部外周、脊髓和皮层水平上疼痛产生器的多种可能性。Altius®系统的开发目的是通过应用于外周神经的袖带电极和植入式脉冲发生器来提供高频神经阻滞(HFNB)治疗。我们报告了一项新颖的临床试验设计,该设计用于首次研究一种有源植入式医疗器械在下肢截肢后疼痛患者中的应用,采用了一项多中心、双盲、随机、有源假对照的临床研究方案,称为QUEST,这是一项正在进行的研究性器械豁免研究,以支持美国食品药品监督管理局的批准。
2021年9月完成了180名受试者的研究入组。受试者被1:1随机分配到治疗组或有源假对照组,进行为期3个月的主要有效性和安全性终点研究。3个月后,有源假对照程序组交叉到治疗程序组,所有受试者继续进行为期12个月的研究终点。研究有效性的成功通过治疗组和对照组在3个月时的应答率之间的优效性检验来确定。应答者定义为在使用治疗的所有疼痛发作中,超过50%的发作在30分钟治疗后疼痛评分降低50%或更多的人。
QUEST研究设计采用有源假对照组来客观评估HFNB治疗的有效性。此外,QUEST中电子日记重复测量数据收集预计将减少疼痛治疗研究中通常观察到的受试者内变异。最后,例如,对健康相关生活质量的纵向测量和疼痛药物的使用可能显示随着时间推移在减少阿片类药物使用方面的有效性。